X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CADILA HEALTHCARE ALKEM LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x - 18.2 - View Chart
P/BV x 6.5 4.1 156.7% View Chart
Dividend Yield % 0.7 1.0 67.5%  

Financials

 ALKEM LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CADILA HEALTHCARE
Mar-18
ALKEM LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,589558 284.8%   
Low Rs1,232362 340.8%   
Sales per share (Unadj.) Rs417.5116.3 359.0%  
Earnings per share (Unadj.) Rs56.317.9 315.1%  
Cash flow per share (Unadj.) Rs64.723.1 279.7%  
Dividends per share (Unadj.) Rs12.703.50 362.9%  
Dividend yield (eoy) %0.90.8 118.3%  
Book value per share (Unadj.) Rs292.985.4 342.9%  
Shares outstanding (eoy) m119.571,023.74 11.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.0 85.5%   
Avg P/E ratio x25.125.7 97.4%  
P/CF ratio (eoy) x21.819.9 109.7%  
Price / Book Value ratio x4.85.4 89.5%  
Dividend payout %22.619.6 115.2%   
Avg Mkt Cap Rs m168,653470,664 35.8%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m9,17118,545 49.5%   
Avg. sales/employee Rs ThNM10,072.7-  
Avg. wages/employee Rs ThNM1,569.1-  
Avg. net profit/employee Rs ThNM1,547.7-  
INCOME DATA
Net Sales Rs m49,915119,049 41.9%  
Other income Rs m1,6451,132 145.3%   
Total revenues Rs m51,561120,181 42.9%   
Gross profit Rs m8,48228,475 29.8%  
Depreciation Rs m1,0065,388 18.7%   
Interest Rs m671911 73.6%   
Profit before tax Rs m8,45123,308 36.3%   
Minority Interest Rs m-114628 -18.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6065,644 28.5%   
Profit after tax Rs m6,73118,292 36.8%  
Gross profit margin %17.023.9 71.0%  
Effective tax rate %19.024.2 78.5%   
Net profit margin %13.515.4 87.8%  
BALANCE SHEET DATA
Current assets Rs m27,06282,005 33.0%   
Current liabilities Rs m15,32460,720 25.2%   
Net working cap to sales %23.517.9 131.5%  
Current ratio x1.81.4 130.8%  
Inventory Days Days6773 90.9%  
Debtors Days Days4198 42.0%  
Net fixed assets Rs m12,61083,703 15.1%   
Share capital Rs m2391,024 23.3%   
"Free" reserves Rs m34,49086,421 39.9%   
Net worth Rs m35,02787,445 40.1%   
Long term debt Rs m1,21225,551 4.7%   
Total assets Rs m54,387180,653 30.1%  
Interest coverage x13.626.6 51.2%   
Debt to equity ratio x00.3 11.8%  
Sales to assets ratio x0.90.7 139.3%   
Return on assets %13.610.6 128.0%  
Return on equity %19.220.9 91.9%  
Return on capital %24.922.0 113.0%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56342,683 15.4%   
Fx outflow Rs m3,01211,242 26.8%   
Net fx Rs m3,55231,441 11.3%   
CASH FLOW
From Operations Rs m7,2599,193 79.0%  
From Investments Rs m1,864-9,737 -19.1%  
From Financial Activity Rs m-9,273515 -1,800.5%  
Net Cashflow Rs m-150-29 517.2%  

Share Holding

Indian Promoters % 66.9 74.8 89.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.3 398.8%  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 11.0 -  
Shareholders   68,381 44,069 155.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Dec 12, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS